At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
REPL Replimune Group Inc.
Not Yet Opened 08-19 16:00:00 EDT
14.81
-0.77
-4.94%
盘后14.89
+0.08+0.53%
19:58 EDT
High15.64Low14.73Vol3.44M
Open15.17D1 Closing15.58Amplitude5.84%
Mkt Cap1.40BTradable Cap1.15BTotal Shares94.22M
T/O51.84MT/O Rate4.44%Tradable Shares77.49M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Replimune Grants CCO Michelle DiNapoli Options for 150,000 Shares at $15.58, Plus 100,000 RSUs
Reuters  ·  04:01
Replimune Grants CCO Michelle DiNapoli Options for 150,000 Shares at $15.58, Plus 100,000 RSUs
Press Release: Replimune Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dow Jones  ·  04:01
Press Release: Replimune Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Trump Picks White House Adviser Heidi Overton to Run FDA, Source Says
Reuters  ·  08-19 08:35
Trump Picks White House Adviser Heidi Overton to Run FDA, Source Says
Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop
TIPRANKS  ·  08-19 03:29
Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop
Jefferies Remains a Buy on Replimune Group (REPL)
TIPRANKS  ·  08-17 23:15
Jefferies Remains a Buy on Replimune Group (REPL)
Replimune files automatic mixed securities shelf
TIPRANKS  ·  08-16
Replimune files automatic mixed securities shelf
Replimune Group, Inc. Files for Mixed Shelf; Size not Disclosed - SEC Filing
THOMSON REUTERS  ·  08-15
Replimune Group, Inc. Files for Mixed Shelf; Size not Disclosed - SEC Filing
Replimune Group Lawsuit Alleges Investors Were Misled Before REPL Stock Drop
TIPRANKS  ·  08-15
Replimune Group Lawsuit Alleges Investors Were Misled Before REPL Stock Drop
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Reuters  ·  08-14
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Replimune Q1 Net Loss Narrows as Expenses Decline
Reuters  ·  08-14
Replimune Q1 Net Loss Narrows as Expenses Decline
Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss
MT Newswires Live  ·  08-14
Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss
Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
Benzinga Earnings  ·  08-14
Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
Replimune FY27 Q1 Net Loss Narrows to $69.8 Million; R&D Expenses Fall to $49.3 Million
Reuters  ·  08-14
Replimune FY27 Q1 Net Loss Narrows to $69.8 Million; R&D Expenses Fall to $49.3 Million
Replimune Group Q1 EPS USD -0.72
THOMSON REUTERS  ·  08-14
Replimune Group Q1 EPS USD -0.72
Baker Bros. Advisors Membeli Saham Replimune Senilai USD 33,01 Juta
Reuters  ·  08-12
Baker Bros. Advisors Membeli Saham Replimune Senilai USD 33,01 Juta
Replimune Amends Filing to Correct Pre-Funded Warrant Beneficial Ownership Limits
Reuters  ·  08-11
Replimune Amends Filing to Correct Pre-Funded Warrant Beneficial Ownership Limits
Replimune Shares Rise After Pricing of Offering
Dow Jones  ·  08-11
Replimune Shares Rise After Pricing of Offering
Replimune Jumps After $150 Mln Equity Offering for Skin Cancer Drug
Reuters  ·  08-11
Replimune Jumps After $150 Mln Equity Offering for Skin Cancer Drug
Replimune Group, - Prices Offering of 9.7 Mln Shares at $12.06 Per Share
THOMSON REUTERS  ·  08-10
Replimune Group, - Prices Offering of 9.7 Mln Shares at $12.06 Per Share
Replimune Group, - Offers 2.7 Mln Pre-Funded Warrants at $12.06 Per Warrant
THOMSON REUTERS  ·  08-10
Replimune Group, - Offers 2.7 Mln Pre-Funded Warrants at $12.06 Per Warrant

Introduction

Company Name.
Replimune Group Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Issue price:
--